Newsroom

NEWS

December 17, 2025

Galux Announces Research Agreement with Boehringer Ingelheim to Advance AI-Driven Protein Design

Read More

NEWS

December 11, 2025

Galux and Seoul National University Develop ‘T-SCAPE,’ an AI for Predicting Immunogenicity of Drug Candidates

Read More

NEWS

December 2, 2025

Galux and Celltrion Enter Strategic Partnership to Co-Develop Next-Generation Multispecific Antibodies for Autoimmune Diseases

Read More

NEWS

November 26, 2025

Galux Achieves Breakthrough by Delivering High-Affinity De Novo Antibodies from Only 50 AI Designs, Marking a New Era in Precision Protein Design

Read More

NEWS

November 14, 2025

Galux and ISU Abxis Sign MOU to Collaborate on AI-Driven Drug Discovery

Read More

NEWS

September 30, 2025

Galux and Woojung Bio Forge Strategic Partnership to Accelerate AI-Driven Therapeutics Development

Read More

NEWS

September 23, 2025

Galux Demonstrates De Novo Antibody Design With Structural and Functional Validation Across Eight Targets

Read More

NEWS

June 11, 2025

Galux and HanAll Biopharma Initiate Strategic Collaboration to Develop AI-Designed Antibody Therapeutics for Cancer

Read More

NEWS

March 17, 2025

Galux Unveils a Study in AI-Powered De Novo Antibody Design for Multiple Therapeutic Targets

Read More

NEWS

September 19, 2024

Galux Unveils Breakthrough AI Technology for Therapeutic Antibody Loop Design

Read More

NEWS

August 26, 2024

Galux and LG Chem Initiate Joint Research on AI-Powered Cancer Drug Development

Read More